Heart failure (HF) is a significant cause of morbidity and mortality worldwide, with few reparative treatment options available. This preliminary trial investigated the potential of Endogenous Stem Cell Mobilization (ESCM), using a plant-based supplement documented to mobilize bone marrow stem cells (BMSCs), to enhance cardiac function in patients with heart failure. This plant-based supplement, Stemregen® Release, contains extracts of Aphanizomenon flos-aquae, sea buckthorn berry, Aloe macroclada, and Fucus vesiculosus. With a consumption of 2 capsules 3 times a day over six months, participants demonstrated substantial improvements in left ventricular ejection fraction (LVEF; 20.3%), reductions in natriuretic peptide (NP; 14.7%) levels, and enhanced quality of life as assessed by the Seattle Angina Questionnaire-7 (SAQ-7; 23.1%). ESCM using Stemregen® Release could be a non-invasive, safe, and effective strategy for improving heart failure outcomes, with broader implications for other degenerative conditions. Further studies are warranted to confirm the mechanisms of action and assess reproducibility in larger cohorts.